Stephen Hahn, FDA commissioner (AP Images)

Stephen Hahn: FDA will make some changes amid Covid-19 per­ma­nent

The FDA will look to per­ma­nent­ly im­ple­ment some of the process­es and poli­cies adopt­ed in its re­sponse to the Covid-19 pan­dem­ic, FDA com­mis­sion­er Stephen Hahn said dur­ing a vir­tu­al brief­ing host­ed by the Al­liance for a Stronger FDA on Mon­day.

Hahn’s state­ments dur­ing the brief­ing close­ly mir­rored state­ments he made in a pre-record­ed video FDA up­loaded to YouTube on Fri­day.

“As this pan­dem­ic has evolved, it was clear to all of us that some FDA process­es need­ed to be ad­just­ed to ac­com­mo­date the ur­gency of the pan­dem­ic and I think the en­tire FDA team has now seen first-hand that we need to take a crit­i­cal look at some of our process­es and poli­cies,” Hahn said.

Hahn added that many of the changes the agency will im­ple­ment “rep­re­sent an ac­cel­er­a­tion of where we were head­ed be­fore,” and in­clude sup­port for de­cen­tral­ized clin­i­cal tri­als, greater use of telemed­i­cine tech­nol­o­gy in clin­i­cal tri­als and work re­lat­ed to lab­o­ra­to­ry-de­vel­oped tests.

Hahn said he has in­struct­ed FDA staff “to iden­ti­fy the lessons learned from this pan­dem­ic and what ad­just­ments may be need­ed, not just to man­age this or fu­ture emer­gen­cies, but how to per­ma­nent­ly make FDA more ef­fi­cient in car­ry­ing out [its] reg­u­la­to­ry re­spon­si­bil­i­ties.”

Ad­di­tion­al­ly, Hahn said FDA is us­ing re­al-world ev­i­dence to mon­i­tor the use of med­ical prod­ucts dur­ing the pan­dem­ic. “We very much used re­al-world ev­i­dence and our Sen­tinel sys­tem and oth­er re­sources to look back at the re­al-world use of di­ag­nos­tic tests and med­ical prod­ucts and then ad­just our au­tho­riza­tions based on that,” he said, adding that re­al-world ev­i­dence can al­so help “to bet­ter un­der­stand dis­ease, de­scribe and mea­sure im­mu­ni­ty [and] un­der­stand the op­er­at­ing char­ac­ter­is­tics of tests.”

Hahn al­so ad­dressed con­flict of in­ter­est con­cerns stem­ming from the role of Cen­ter for Drug Eval­u­a­tion and Re­search (CDER) Di­rec­tor Janet Wood­cock and Cen­ter for Bi­o­log­ics Eval­u­a­tion and Re­search (CBER) Di­rec­tor Pe­ter Marks in over­see­ing the re­view of prod­ucts de­vel­oped to treat or pre­vent Covid-19.

Wood­cock and Marks were both ini­tial­ly slat­ed to take lead­er­ship roles on the Trump ad­min­is­tra­tion’s Op­er­a­tion Warp Speed. Short­ly af­ter the an­nounce­ment, Marks left his new role to fo­cus on head­ing CBER, while Wood­cock was tem­porar­i­ly re­as­signed to the Of­fice of the Com­mis­sion­er dur­ing her work on Op­er­a­tion Warp Speed.

“We have been very clear in writ­ing, but al­so ver­bal­ly, that we will main­tain our reg­u­la­to­ry in­de­pen­dence, so that Janet [Wood­cock] will not par­tic­i­pate in the reg­u­la­to­ry de­ci­sions around ther­a­peu­tics and Pe­ter and I will stay out­side of any de­ci­sion-mak­ing that Op­er­a­tion Warp Speed has to make with re­spect to med­ical prod­ucts so that we can main­tain our in­de­pen­dence,” Hahn said.

For a look at all End­points News coro­n­avirus sto­ries, check out our spe­cial news chan­nel.

RAPS: First pub­lished in Reg­u­la­to­ry Fo­cus™ by the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety, the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care prod­ucts. Click here for more in­for­ma­tion.

Biotech in­vestors and CEOs see two paths to growth, but are they equal­ly vi­able?

The dynamic in the biotech market has been highly volatile in the last few years, from the high peaks immediately after the COVID vaccine in 2021, to the lowest downturns of the last 20 years in 2022. This uncertainty makes calling the exact timing of the market’s turn something of a fool’s errand, according to Dr. Chen Yu, Founder and Managing Partner of TCG Crossover (TCG X). He speaks with RBC’s Noël Brown, Head of US Biotechnology Investment Banking, about the market’s road ahead and two possible paths for growth.

In AstraZeneca's latest campaign, wild eosinophils called Phils personify the acting up often seen in uncontrolled asthma

As­traZeneca de­buts an­noy­ing pur­ple ‘Phil’ crea­tures, per­son­i­fied asth­ma eosinophils ‘be­hav­ing bad­ly’

There are some odd-looking purple creatures lurking around the halls of AstraZenca lately. The “Phil” character cutouts are purple, personified eosinophils with big buggy eyes and wide mouths, and they’re a part of AZ’s newest awareness effort to help people understand eosinophilic asthma.

The “Asthma Behaving Badly” characters aren’t only on the walls at AZ to show the new campaign to employees, however. The “Phils” are also showing up online on the campaign website, and in digital and social ads and posts on Facebook and Instagram.

Casey McPherson shows his daughters Rose (left) and Weston around Everlum Bio, a lab that he co-founded to spark a treatment for Rose and others with ultra-rare conditions. (Ilana Panich-Linsman)

Fa­ther starts lab af­ter in­tel­lec­tu­al prop­er­ty is­sues stymie rare dis­ease drug de­vel­op­ment

Under bright lab lights, Casey McPherson holds his 6-year-old daughter, Rose. His free hand directs Rose’s gaze toward a computer screen with potential clues in treating her one-of-a kind genetic condition.

Gray specks on the screen show her cells that scientists reprogrammed with the goal of zeroing in on a custom medicine. McPherson co-founded the lab, Everlum Bio, to spark a treatment for Rose — and others like her. A regarded singer-songwriter, McPherson never imagined going into drug development.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,300+ biopharma pros reading Endpoints daily — and it's free.

Robert Califf, FDA commissioner (via AP Images)

User fees in ac­tion: FDA un­veils new short­ened sup­ple­ment re­view, rare dis­ease pi­lots

Thanks to PDUFA VII, signed into law last Friday by President Joe Biden, the FDA this week unveiled two new industry-friendly pilot programs to advance new rare disease endpoints via additional meetings, and to shorten FDA review times for supplemental apps aimed at unmet medical needs.

The agency this week released eagerly-awaited details behind the shortened pilot, known as the Split Real Time Application Review or STAR pilot program, which will speed up certain FDA reviews of efficacy supplements across all therapeutic areas (thanks to earlier submissions of data), but only for those that propose addressing an unmet medical need.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,300+ biopharma pros reading Endpoints daily — and it's free.

Ying Huang, Legend CEO

Lentivi­ral vec­tor ramp-up: J&J and Leg­end to in­vest $500M in New Jer­sey man­u­fac­tur­ing to sup­port Carvyk­ti

In response to a question on manufacturing scale at Legend Biotech’s R&D day yesterday, the company’s top exec said its partnership with Johnson & Johnson will be doubling its investment in its New Jersey manufacturing center and will be investing a total of $500 million.

With an eye on their BCMA-directed CAR-T therapy Carvykti (cilta-cel), approved in February as a fifth-line treatment for multiple myeloma, Legend CEO Ying Huang said that the ramp-up in production and the decision to manufacture its own lentiviral vectors — currently in shortage worldwide — means they won’t have to deal with that shortage.

Kite Phar­ma gets FDA to sign off on new Cal­i­for­nia-based vec­tor man­u­fac­tur­ing fa­cil­i­ty

Kite Pharma just got FDA approval to kick off operations at a new manufacturing campus.

The cancer-focused, CAR-T cell therapy player made the announcement Monday, saying that the federal regulatory agency gave the green light to Kite’s 100,000 square-foot, retroviral vector manufacturing facility in Oceanside, CA.

Kite’s global head of technical operations Chris McDonald tells Endpoints News that the facility has been in the works for about four years, after Kite teamed up with its parent company Gilead. Gilead acquired Kite Pharma for just shy of $12 billion in 2017.

Mar­ket­ingRx roundup: No­var­tis re­cruits NFL coach for Leqvio cam­paign; Pfiz­er pro­motes ‘Sci­ence’ merch on so­cial me­dia

Novartis is turning to a winning coach to talk about Leqvio and the struggles of high cholesterol — including his own. Bruce Arians, the retired NFL head coach of the Arizona Cardinals and Super Bowl-winning Tampa Bay Buccaneers, is partnering with the pharma for its “Coaching Cholesterol” digital, social and public relations effort.

In the campaign, Arians talks about the potential for “great comebacks” in football and heart health. Once nicknamed a “quarterback whisperer,” he is now retired from fulltime coaching (although still a front-office consultant for Tampa Bay), and did a round of media interviews for Novartis, including one with People and Forbes.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,300+ biopharma pros reading Endpoints daily — and it's free.

Amy West, Novo Nordisk head of US digital innovation and transformation (Illustration: Assistant Editor Kathy Wong for Endpoints News)

Q&A: No­vo Nordisk dig­i­tal in­no­va­tion chief Amy West dis­cuss­es phar­ma pain points and a health­care 'easy but­ton’

Amy West joined Novo Nordisk more than a decade ago to oversee marketing strategies and campaigns for its US diabetes portfolio. However, her career path shifted into digital, and she hasn’t looked back. West went from leading Novo’s first digital health strategy in the US to now heading up digital innovation and transformation.

She’s currently leading the charge at Novo Nordisk to not only go beyond the pill with digital marketing and health tech, but also test, pilot and develop groundbreaking new strategies needed in today’s consumerized healthcare world.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Marc Dunoyer, Alexion CEO (AstraZeneca via YouTube)

Up­dat­ed: As­traZeneca nabs a small rare dis­ease gene ther­a­py play­er for 667% pre­mi­um

AstraZeneca is kicking off the fourth quarter with a little M&A Monday for a gene editing player recently overcoming a second clinical hold to its only program in human studies.

The Big Pharma and its subsidiary Alexion are buying out little LogicBio for $2.07 per share. That’s good for a massive 667% premium over its Friday closing price, when it headed into the weekend at 27 cents and just weeks after Nasdaq said LogicBio would have to delist, which has been put on hold as the biotech requests a hearing. It’s one of two biotech deals to commence October, alongside the news of Incyte buying a vitiligo-focused biotech.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,300+ biopharma pros reading Endpoints daily — and it's free.